erlotinib has been researched along with 2,6-dihydroxyanthraquinone in 1 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (2,6-dihydroxyanthraquinone) | Trials (2,6-dihydroxyanthraquinone) | Recent Studies (post-2010) (2,6-dihydroxyanthraquinone) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 24 | 0 | 6 |
| Protein | Taxonomy | erlotinib (IC50) | 2,6-dihydroxyanthraquinone (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 1.1 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 3.8 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 5.62 | |
| Estrogen receptor beta | Homo sapiens (human) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choowongkomon, K; Eurtivong, C; Jiwacharoenchai, N; Niwetmarin, W; Ruchirawat, S; Saruengkhanphasit, R; Seetaha, S | 1 |
1 other study(ies) available for erlotinib and 2,6-dihydroxyanthraquinone
| Article | Year |
|---|---|
Discovery of potent antiproliferative agents from selected oxygen heterocycles as EGFR tyrosine kinase inhibitors from the U.S. National Cancer Institute database by in silico screening and bioactivity evaluation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; ErbB Receptors; Heterocyclic Compounds; Humans; Molecular Docking Simulation; Molecular Structure; National Cancer Institute (U.S.); Oxygen; Protein Kinase Inhibitors; Structure-Activity Relationship; United States; Xanthenes | 2022 |